Literature DB >> 22967411

[Clinical features and survival analysis in primary myelodysplastic syndromes patients with immunological abnormalities].

Bing Li1, Ze-feng Xu, Rui Cui, Yue-dan Chen, Tao Su, Tian-jiao Zhang, Li-wei Fang, Hong-li Zhang, Tie-jun Qin, Zhi-jian Xiao.   

Abstract

OBJECTIVE: To analyze the clinical features and survival time in primary myelodysplastic syndromes (MDS) patients accompanied with immunological abnormalities.
METHODS: The clinical information, laboratory findings and survival time in 194 untreated primary MDS patients with complete immunological laboratory tests or a past history of autoimmune disease were analyzed retrospectively.
RESULTS: There were 37/194 cases (19.07%) with autoimmune abnormalities, including 16/194 (8.25%) with autoimmune disease and 21/194 asymptomatic cases (10.82%) with serologic immunological abnormalities only. There was significant differences in the distribution of age < 60 years old, female, CD4(+)T-cell/CD8(+)T-cell ration < 1 and trisomy 8 (P < 0.05) between the cases with autoimmune disease and without autoimmune abnormalities. The former had a higher 2-year OS, but there was no significance (P = 0.065). There was no significant differences in the distribution of age, MDS-subtype, IPSS risk groups, haemoglobin, absolute neutrophil count, platelets count, the severity of anemia and neutropenia, high level of serologic TNF, chromosomal abnormalities, cytogenetic risk groups and bone marrow cellularity (P > 0.05).
CONCLUSION: MDS patients with autoimmune disease are mainly female and younger than 60 years old, with high proportion of trisomy 8 and better prognosis.

Entities:  

Mesh:

Year:  2012        PMID: 22967411

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  1 in total

1.  Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.

Authors:  Naibo Hu; Tiejun Qin; Xiaoyan Du; Bingyi Wang; Xiaoyun Wang; Zefeng Xu; Lijuan Pan; Shiqiang Qu; Zhijian Xiao
Journal:  Med Sci Monit       Date:  2021-01-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.